Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have been given a consensus rating of “Hold” by the eight research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $25.20.

Several research analysts have recently issued reports on EIKN shares. Wall Street Zen cut shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Wedbush cut their price target on shares of Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings began coverage on shares of Eikon Therapeutics in a research report on Monday, June 1st. They issued a “sell (e-)” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a report on Tuesday, June 2nd.

Eikon Therapeutics Price Performance

NASDAQ:EIKN traded down $0.64 during trading hours on Friday, hitting $10.58. The company’s stock had a trading volume of 281,982 shares, compared to its average volume of 382,655. Eikon Therapeutics has a 52-week low of $7.90 and a 52-week high of $17.40. The company has a market capitalization of $572.79 million and a PE ratio of -4.30. The company has a fifty day simple moving average of $10.50.

Eikon Therapeutics (NASDAQ:EIKN) last issued its earnings results on Monday, March 30th. The company reported ($26.23) earnings per share for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.